Cargando…

Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study

BACKGROUND: In breast cancer and prostate cancer patients, bone metastases (BM) present the main cause of morbidity and often cause debilitating pain, impaired functioning and subsequent deterioration of quality of life (QoL). The management of BM is still challenging. Maintenance or improvement in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakob, Andreas, Zahn, Mark-Oliver, Nusch, Arnd, Werner, Thorsten, Schnell, Roland, Frank, Melanie, Hamm, Nicole, Däßler, Klaus-Ulrich, Losem, Christoph, Welslau, Manfred, Hoevel, Petra, Potthoff, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941198/ https://www.ncbi.nlm.nih.gov/pubmed/35340302 http://dx.doi.org/10.1016/j.jbo.2022.100420

Ejemplares similares

Importance of antiresorptive therapies for patients with bone metastases from solid tumors
por: Talreja, Draupadi B
Publicado: (2012)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
por: Navarro‐Gonzalez, Elena
Publicado: (2022)

Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration
por: Mjelstad, AnneMarthe, et al.
Publicado: (2019)

New Antiresorptive Therapies for Postmenopausal Osteoporosis
por: Choi, Hee-Jeong
Publicado: (2015)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018)

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
por: Eastell, Richard, et al.
Publicado: (2022)

Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis
por: Ota, Seiya, et al.
Publicado: (2016)

AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany
por: Zahn, Mark-Oliver, et al.
Publicado: (2019)

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
por: Holen, I, et al.
Publicado: (2006)

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
por: Ottewell, PD, et al.
Publicado: (2006)

Medication burden of Saudi Arabian women receiving antiresorptive therapy
por: Sadat-Ali, Mir, et al.
Publicado: (2012)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
por: Ekholm, Heidi M., et al.
Publicado: (2021)

Composition and Properties of Saliva in Patients with Osteoporosis Taking Antiresorptive Drugs
por: Sobczak-Jaskow, Hanna, et al.
Publicado: (2023)

The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis
por: Agarwal, Amil R., et al.
Publicado: (2023)

Antiresorptive Activity of Bacillus-Fermented Antler Extracts: Inhibition of Osteoclast Differentiation
por: Choi, Sik-Won, et al.
Publicado: (2013)

Disulfiram Attenuates Osteoclast Differentiation In Vitro: A Potential Antiresorptive Agent
por: Ying, Hua, et al.
Publicado: (2015)

Dental care for patients taking antiresorptive drugs: a literature review
por: Song, Minju
Publicado: (2019)

Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw
por: Kim, Ha Young
Publicado: (2021)

Pharyngeal spreading of peri-implant infections under antiresorptive/antiangiogenic therapy
por: Kern, Karsten, et al.
Publicado: (2021)

Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022)

Use and risk of side effects of antiresorptive medication in people with intellectual disabilities
por: Frighi, Valeria, et al.
Publicado: (2022)

Relationship between Drug Holidays of Antiresorptive Agents and Surgical Outcomes in Cancer Patients with Medication-Related Osteonecrosis of the Jaw
por: Otsuru, Mitsunobu, et al.
Publicado: (2022)

Dental implants in patients treated with antiresorptive medication – a systematic literature review
por: Walter, Christian, et al.
Publicado: (2016)

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review
por: Qayoom, I., et al.
Publicado: (2018)

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
por: Taguchi, Akira, et al.
Publicado: (2017)

Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center
por: Ferreira, Vitor Hugo Candido, et al.
Publicado: (2021)

Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs
por: del Real, Álvaro, et al.
Publicado: (2022)

Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
por: Zhang, Chenggui, et al.
Publicado: (2021)

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
por: Migliorini, Filippo, et al.
Publicado: (2022)

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication
por: Yanaguizawa, Wellington Hideaki, et al.
Publicado: (2022)

Influence of antiresorptive/antiangiogenic therapy on the extension of experimentally induced peri-implantitis lesions
por: Schwarz, Frank, et al.
Publicado: (2023)

Effects of antiresorptive agents on body composition: a case-control retrospective study
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2023)

Two Cases of External Auditory Canal Osteonecrosis in Patients on Antiresorptive Therapy for Osteoporosis
por: Kumar, Shejil, et al.
Publicado: (2023)

P02 When should we stop the antiresorptive medications in patients with osteoporosis?
por: Mohareb, Marwa, et al.
Publicado: (2023)

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?
por: Oteri, Giacomo, et al.
Publicado: (2018)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
por: Decker, Thomas, et al.
Publicado: (2017)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
por: Dechow, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fo5fp2ub74dk0eb3vc9pj5o1n0